Estrogen Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Estrogen Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer [Phase 4]
Phase 4 clinical trial updating on the use of the PET tracer [18F]-FES to image estrogen receptor–positive breast cancer with brain metastas…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC [Phase 3]
Phase 3 trial evaluating adjuvant elacestrant versus standard endocrine therapy in high-risk ER+/HER2- breast cancer is currently not recrui…
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: Breast Re-irradiation After Second Ipsilateral Lumpectomy [NA]
This document provides an update on a clinical trial evaluating breast re-irradiation after a second ipsilateral lumpectomy.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial [Phase 2]
Phase 2 trial evaluating imlunestrant in combination with abemaciclib for estrogen receptor-positive breast cancer with minimal residual dis…
-
CLINICAL_TRIALS research · 2025-10-30Clinical Trial Update: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer [Phase 2]
A Phase 2 clinical trial update for Z-Endoxifen in premenopausal women with ER-positive, HER2-negative breast cancer, currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-22Clinical Trial Update: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer [Phase 1]
Olema Pharmaceuticals reports a Phase 1b trial evaluating OP-1250 (palazestrant) in combination with ribociclib, alpelisib, everolimus, or a…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating elacestrant alone versus elacestrant plus a CDK4/6 inhibitor in ER-positive, HER2-negative advanced or met…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease [Phase 3]
Phase 3 trial comparing AZD9833 plus palbociclib versus anastrozole plus palbociclib in ER-positive, HER2-negative breast cancer patients wh…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer [Phase 2]
Phase 2 trial investigating stereotactic body radiation therapy with FES PET/CT imaging for oligoprogressive estrogen receptor–positive meta…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating adaptive therapy with capecitabine for metastatic estrogen receptor-positive, HER2-negative breast ca…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer [Phase 1]
A Phase 1 trial update reports completion of results for ARV-471 in combination with everolimus in advanced or metastatic estrogen receptor‑…
-
FDA approval · 2025-09-25FDA Approved: INLURIYO — Original Application (Eli Lilly and Company)
FDA approved INLURIYO (imlunestrant) from Eli Lilly in an original NDA, an oral selective estrogen receptor degrader for estrogen receptor–p…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer. [NA]
This clinical trial update describes a University Ghent study evaluating a novel technique to identify tumor-specific targets for the deploy…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) [Phase 3]
Phase 3 clinical trial investigating elacestrant for estrogen receptor-positive, HER2-negative breast cancer with ctDNA relapse (TREAT ctDNA…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: [18F]FES PET/CT in Endocrine Refractory Breast Cancer [Phase 2]
Phase 2 trial evaluating [18F]fluoroestradiol PET/CT imaging in estrogen receptor-positive breast cancer has completed.
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs [Phase 2]
A Phase 2 trial of datopotamab deruxtecan (DATO-BASE) for breast cancer with brain metastases is currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor [Phase 2]
Phase 2 trial evaluating lenvatinib plus letrozole versus fulvestrant in metastatic ER+/HER2- breast cancer after progression on an aromatas…
-
CLINICAL_TRIALS trial_result · 2025-07-20Clinical Trial Update: Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer [Phase 2]
Phase 2 trial evaluating the impact of combining endocrine therapy with abemaciclib on host and tumor immune cell repertoire in advanced ER+…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Role of the Immune Environment in Response to Therapy in Breast Cancer
A clinical trial update from Penn Medicine describes a study on how the immune environment influences response to therapy in breast cancer, …
-
CLINICAL_TRIALS trial_result · 2025-06-26Clinical Trial Update: A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers [Phase 2]
This Phase 2 clinical trial aims to determine if estrogen can slow the growth of estrogen receptor-positive breast cancers. The study, spons…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial update (SAPPHO) evaluating sequential curative-intent therapy in newly diagnosed de novo HER2-positive metastatic bre…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) [Phase 2]
Phase 2 clinical trial update (KePreSt) assessing the effects of ketorolac and pregabalin in early-stage, estrogen receptor-positive breast …
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk [Phase 4]
A Phase 4 clinical trial evaluating ovarian function suppression in premenopausal, node-positive, estrogen receptor-positive, HER2-negative …
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter) [Phase 2]
A Phase 2 trial evaluating neoadjuvant therapy for ER+/HER2- breast cancer comparing High-Intensity Focused Ultrasound (HIFU) plus toripalim…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: Biology Guided Therapy for Breast Cancer for ER Positive [Phase 2]
A Phase 2 biology-guided therapy trial for estrogen receptor-positive breast cancer was terminated, with results posted.